William Blair Has Bearish Estimate for AXSM Q1 Earnings
William Blair cut their Q1 2025 earnings per share estimates for Axsome Therapeutics in a report issued on Tuesday, February ...
Axsome Therapeutics price target raised to $200 from $190 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Axsome Therapeutics (AXSM) to $200 from $190 and keeps a Buy rating on the shares following ...
Yahoo Finance3d
Axsome Therapeutics Inc (AXSM) Q4 2024 Earnings Call Highlights: Robust Revenue Growth Amid ...
Axsome Therapeutics Inc (NASDAQ:AXSM) reported strong financial performance with total net product revenue of $386 million for 2024, reflecting high double-digit year-over-year growth. The company ...
Seeking Alpha4d
AXSM Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial ...
Axsome Therapeutics price target raised to $200 from $190 at Truist
Truist raised the firm’s price target on Axsome Therapeutics (AXSM) to $200 from $190 and keeps a Buy rating on the shares. The company’s Q4 ...
Nasdaq4d
Axsome Q4 Loss Wider Than Expected, Auvelity Drives Sales Growth
Axsome Therapeutics AXSM incurred an adjusted loss of 96 cents per share in the fourth quarter of 2024, wider than the Zacks Consensus Estimate of a loss of 90 cents. The company had incurred a ...
Morningstar2d
Axsome Therapeutics Inc AXSM
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...